This Article Order Full text via Infotrieve Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Geratz, J. D. Articles by Pryzwansky, K. B. Search for Related Content PubMed PubMed Citation Articles by Geratz, J. D. Articles by Pryzwansky, K. B.

American Journal of Pathology, Vol 139, 921-931, Copyright © 1991 by American Society for Investigative Pathology

REGULAR ARTICLES

Streptococcal cell wall-induced systemic disease. Beneficial effects of trans-bis(5-amidino-2-benzimidazolyl)ethene, a novel, macrophage- directed anti-inflammatory agent [published erratum appears in Am J Pathol 1992 Jan;140(1):following Table of Contents]

JD Geratz, RR Tidwell, RJ Lombardy, JH Schwab, SK Anderle and KB Pryzwansky
School of Medicine, Department of Pathology, University of North Carolina, Chapel Hill 27599.

Previously bis(5-amidino-2-benzimidazolyl)methane (BABIM) was identified as a strong inhibitor of the multisystem inflammatory disease induced in Lewis rats by injection of streptococcus group A cell wall-derived peptidoglycan polysaccharide (PG-APS). A BABIM derivative, trans-bis(5-amidino-2-benzimidazolyl)ethene (BBE), has attracted attention because of striking qualitative and quantitative differences in its activities when compared with the parent compound. BBE could control destructive tibial osteitis and necrotizing granulomatous splenitis and hepatitis, regardless if given in a preventive or curative mode. The compound had little effect on synovitis, however. BABIM, on the other hand, was active against synovitis and osteitis, but not against splenic granuloma formation. To be effective, it needed to be applied in a preventive mode. BBE caused a characteristic enlargement of PG-APS-laden splenic and hepatic macrophages suggesting that those cells represent targets of the inhibitor. BBE may be a powerful tool for the study of granulomatous lesions.

This article has been cited by other articles:

				J. E. Hall, J. E. Kerrigan, K. Ramachandran, B. C. Bender, J. P. Stanko, S. K. Jones, D. A. Patrick, and R. R. Tidwell Anti-Pneumocystis Activities of Aromatic Diamidoxime Prodrugs Antimicrob. Agents Chemother., March 1, 1998; 42(3): 666 - 674. [Abstract] [Full Text]